Powered by: Motilal Oswal
2026-11-18 01:29:17 pm | Source: Accord Fintech
Glenmark Pharmaceuticals rises as its arm submits IND application to USFDA for ISB 2301
Glenmark Pharmaceuticals rises as its arm submits IND application to USFDA for ISB 2301

Glenmark Pharmaceuticals is currently trading at Rs. 2650.60, up by 36.80 points or 1.41% from its previous closing of Rs. 2613.80 on the BSE.

The scrip opened at Rs. 2665.00 and has touched a high and low of Rs. 2680.00 and Rs. 2627.30 respectively. So far 17585 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2713.75 on 09-Nov-2026 and a 52 week low of Rs. 1818.40 on 18-Nov-2025.

Last one week high and low of the scrip stood at Rs. 2,685.00 and Rs. 2609.00 respectively. The current market cap of the company is Rs. 74874.21 crore.

The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 39.19% and 14.17% respectively.

Glenmark Pharmaceuticals’ biotech arm -- Ichnos Glenmark Innovation, Inc. (IGI) has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (USFDA) for ISB 2301. ISB 2301 is a first-in-class, investigational multispecific immune cell activator designed to target three tumor-associated antigens and engage both T cells and NK cells. This pentaspecific molecule combines five binding specificities: three tumor-associated antigens, plus T-cell and NK-cell activation. By combining tumor-cell recognition with complementary immune activity, ISB 2301 is being developed to address biological heterogeneity and immune-suppressive features of solid tumors.

Disclaimer: The content of this article is for informational purposes only and should not be considered financial or investment advice. Investments in financial markets are subject to market risks, and past performance is not indicative of future results. Readers are strongly advised to consult a licensed financial expert or advisor for tailored advice before making any investment decisions. The data and information presented in this article may not be accurate, comprehensive, or up-to-date. Readers should not rely solely on the content of this article for any current or future financial references. To Read Complete Disclaimer Click Here